[smartdoctor] Re: Afera Pfizer
- From: Zrinko Karlović <zrinko.karlovic@xxxxxxxxx>
- To: smartdoctor@xxxxxxxxxxxxx
- Date: Fri, 10 Aug 2012 11:34:42 +0200
Vjeka, počni stavljati naljepnice na zidove. Kad ih se dovoljno nakupi, a
kako je krenulo neće trebati dugo čekati, više nećeš morati farbati
zidove. I evo ti korupcijske afere, udružena zločinačka organizacija
potkupila te besplatnim soboslikarskim radovima!
2012/8/10 vjeka <vjekoslava.amerl.sakic@xxxxxxxxx>
> Bravo Saša,
> to je to! Od silne korupcije ne znam kako mogu spavati. Glavne su mi
> naljepnice po radnom stolu koje ostave da ne zaboravimo napisati taj i taj
> lijek. Vjeka
> On Aug 10, 2012, at 11:24 AM, J Soic wrote:
>
>
> Ovaj bih mail objavila u javnim gladilima u ime svih obiteljskih lijecnika.
>
> Sent from Yahoo! Mail on Android
>
> ------------------------------
> * From: * aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx>;
> * To: * smartdoctor@xxxxxxxxxxxxx <smartdoctor@xxxxxxxxxxxxx>;
> * Subject: * [smartdoctor] Re: Afera Pfizer
> * Sent: * Fri, Aug 10, 2012 7:56:42 AM
>
> Dragi svi,
> nekako mi se čini da je farmaceutska tvrtka s dva nježna ženska imena u
> nazivu nadmašila Pfizer, barem u RH: Forteo, Byetta, Zypadhera...uvjeren
> sam da ti lijekovi nisu osvanuli na listi HZZO-a posredovanjem i zaslugom
> obiteljskih liječnika.
>
> Molim da uočite da smo napokon izjednačeni s uglednim profesorima iz
> različitih odbora za lijekove i predstojnicima klinika,ako već ne po
> stručnosti, onda po koruptivnom potencijalu.. Naglasak je na potencijalu,
> jer sumnjam da bilo tko od nas ima inozemne bankovne račune u koje redovito
> mjesečno kapne koja tisućica eura, i pun salon trofeja s afričkih safarija.
> Ako uzmemo da prosječni SLOM propiše lijekova u vrijednosti barem milijun
> HRK godišnje, pa još uzmemo u račun od novinara spominjanih
> 12%, farmaceutske nam kuće duguju barem 2-3 apartmana na moru ( čak i ako
> odbijemo kemijske, ručnike, ruksake i kotizacije za kongrese OM- imamo ih
> čak četiri godišnje, što jasno ukazuje da nam je samo od farmaceutskih
> tvrtki plaćeni nerad na pameti).
>
> Još nešto, gdje su u toj koruptivnoj priči magistre/i farmacije? Novinari
> ili misle da one/i ne igraju tu nikakvu ulogu, ili ih drže prvenstveno
> trgovcima kojima razni rabati i nagradna putovanja spadaju u opis radnog
> mjesta.
>
> Pitanje za medije: Ako nas neka generička firma (takve uglavnom surađuju s
> OM) plaćanjem nekog od kongresa OM motivira na propisivanje njihovih
> lijekova koji su najjeftiniji među paralelama, i na taj način smanjimo
> HZZ-u troškove za desetak posto, je li to baš takav sukob interesa zbog
> kojega smo zaslužili stup srama?
>
> Mislim da bi u ovom trenutku mi kao obiteljski liječnici trebali odigrati
> proaktivan potez prema farmaceustkim tvrtkama, a zašto ne i prema
> HZZO-u, sa zahtjevom da većinu stručnih predavanja za obiteljske drže
> obiteljski liječnici, uz honorar daleko niži od bolničkih kolega, a razliku
> bi farmaceutske kuće mogle transparentno uložiti u fond za opremanje
> ambulanti. Time bi javnosti pokazali da nam je temeljni cilj pružanje što
> kvalitetnije usluge svojim pacijentima, a jedini način "bogaćenja" bio bi
> preko DTP postupaka (delimitiranih) koje bi odrađivali uz pomoć te opreme
> (koja može biti i u vlasništvu HZZO-a, da je slučajno ne bi preprodavali na
> "crnom" tržištu).
>
>
> Pozdrav, Saša
>
>
>
>
>
>
>
> *From:* Leonardo Bressan <ordinacija.dr.leonardo.bressan@xxxxxxxxx>
> *To:* smartdoctor@xxxxxxxxxxxxx
> *Sent:* Friday, August 10, 2012 8:48 AM
> *Subject:* [smartdoctor] Afera Pfizer
>
> SEC Charges Pfizer with FCPA Violations
> *FOR IMMEDIATE RELEASE
> 2012-152*
> *Washington, D.C., Aug. 7, 2012** - *The Securities and Exchange
> Commission today charged Pfizer Inc. with violating the Foreign Corrupt
> Practices Act (FCPA) when its subsidiaries bribed doctors and other health
> care professionals employed by foreign governments in order to win business.
> The SEC alleges that employees and agents of Pfizer's subsidiaries in
> Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and
> Serbia made improper payments to foreign officials to obtain regulatory and
> formulary approvals, sales, and increased prescriptions for the company's
> pharmaceutical products. They tried to conceal the bribery by improperly
> recording the transactions in accounting records as legitimate expenses for
> promotional activities, marketing, training, travel and entertainment,
> clinical trials, freight, conferences, and advertising.
> Additional Materials
>
> - SEC Complaint Against
> Pfizer<http://www.sec.gov/litigation/complaints/2012/comp-pr2012-152-pfizer.pdf>
> - SEC Complaint Against
> Wyeth<http://www.sec.gov/litigation/complaints/2012/comp-pr2012-152-wyeth.pdf>
> - More SEC FCPA Cases<http://www.sec.gov/spotlight/fcpa/fcpa-cases.shtml>
>
> The SEC separately charged another pharmaceutical company that Pfizer
> acquired a few years ago - Wyeth LLC - with its own FCPA violations. Pfizer
> and Wyeth agreed to separate settlements in which they will pay more than
> $45 million combined to settle their respective charges. In a parallel
> action, the Department of Justice announced that Pfizer H.C.P. Corporation
> agreed to pay a $15 million penalty to resolve its investigation of FCPA
> violations.
> "Pfizer subsidiaries in several countries had bribery so entwined in their
> sales culture that they offered points and bonus programs to improperly
> reward foreign officials who proved to be their best customers," said Kara
> Brockmeyer, Chief of the SEC Enforcement Division's Foreign Corrupt
> Practices Act Unit. "These charges illustrate the pitfalls that exist for
> companies that fail to appropriately monitor potential risks in their
> global operations."
> According to the SEC's complaint against Pfizer filed in U.S. District
> Court for the District of Columbia, the misconduct dates back as far as
> 2001. Employees of Pfizer's subsidiaries authorized and made cash payments
> and provided other incentives to bribe government doctors to utilize Pfizer
> products. In China, for example, Pfizer employees invited "high-prescribing
> doctors" in the Chinese government to club-like meetings that included
> extensive recreational and entertainment activities to reward doctors' past
> product sales or prescriptions. Pfizer China also created various "point
> programs" under which government doctors could accumulate points based on
> the number of Pfizer prescriptions they wrote. The points were redeemed for
> various gifts ranging from medical books to cell phones, tea sets, and
> reading glasses. In Croatia, Pfizer employees created a "bonus program" for
> Croatian doctors who were employed in senior positions in Croatian
> government health care institutions. Once a doctor agreed to use Pfizer
> products, a percentage of the value purchased by a doctor's institution
> would be funneled back to the doctor in the form of cash, international
> travel, or free products.
> According to the SEC's complaint, Pfizer made an initial voluntary
> disclosure of misconduct by its subsidiaries to the SEC and Department of
> Justice in October 2004, and fully cooperated with SEC investigators.
> Pfizer took such extensive remedial actions as undertaking a comprehensive
> worldwide review of its compliance program.
> The SEC further alleges that Wyeth subsidiaries engaged in FCPA violations
> primarily before but also after the company's acquisition by Pfizer in late
> 2009. Starting at least in 2005, subsidiaries marketing Wyeth nutritional
> products in China, Indonesia, and Pakistan bribed government doctors to
> recommend their products to patients by making cash payments or in some
> cases providing BlackBerrys and cell phones or travel incentives. They
> often used fictitious invoices to conceal the true nature of the payments.
> In Saudi Arabia, Wyeth's subsidiary made an improper cash payment to a
> customs official to secure the release of a shipment of promotional items
> used for marketing purposes. The promotional items were held in port
> because Wyeth Saudi Arabia had failed to secure a required Saudi Arabian
> Standards Organization Certificate of Conformity.
> Following Pfizer's acquisition of Wyeth, Pfizer undertook a risk-based
> FCPA due diligence review of Wyeth's global operations and voluntarily
> reported the findings to the SEC staff. Pfizer diligently and promptly
> integrated Wyeth's legacy operations into its compliance program and
> cooperated fully with SEC investigators.
> In settling the SEC's charges, Wyeth neither admitted nor denied the
> allegations. Pfizer consented to the entry of a final judgment ordering it
> to pay disgorgement of $16,032,676 in net profits and prejudgment interest
> of $10,307,268 for a total of $26,339,944. Wyeth also is required to report
> to the SEC on the status of its remediation and implementation of
> compliance measures over a two-year period, and is permanently enjoined
> from further violations of Sections 13(b)(2)(A) and 13(b)(2)(B) of the
> Securities Exchange Act of 1934. Wyeth consented to the entry of a final
> judgment ordering it to pay disgorgement of $17,217,831 in net profits and
> prejudgment interest of $1,658,793, for a total of $18,876,624. As a Pfizer
> subsidiary, the status of Wyeth's remediation and implementation of
> compliance measures will be subsumed in Pfizer's two-year self-reporting
> period. Wyeth also is permanently enjoined from further violations of
> Sections 13(b)(2)(A) and 13(b)(2)(B) of the Exchange Act. The settlements
> are subject to court approval.
> The SEC's investigation was conducted by Michael Catoe and Charles Cain of
> the Enforcement Division's FCPA Unit. The SEC acknowledges the assistance
> of the U.S. Department of Justice's Criminal Division's Fraud Section and
> the Federal Bureau of Investigation in this matter.
> # # #
>
> *http://www.sec.gov/news/press/2012/2012-152.htm*
>
>
>
>
Other related posts:
